Yahoo
NasdaqGM - Delayed Quote USD

Summit Therapeutics Inc. (SMMT)

16.12 -5.34 (-24.91%)
At close: May 1 at 4:00:00 PM EDT
16.31 +0.19 (+1.21%)
Pre-Market: 9:16:08 AM EDT
Trade SMMT on Coinbase
Chart Range Bar
Loading chart for SMMT
  • Previous Close 21.46
  • Open 16.02
  • Bid 16.07 x 1100
  • Ask 16.16 x 5200
  • Day's Range 15.14 - 16.81
  • 52 Week Range 13.83 - 30.98
  • Volume 18,118,769
  • Avg. Volume 3,193,593
  • Market Cap (intraday) 12.507B
  • Beta (5Y Monthly) -1.25
  • PE Ratio (TTM) --
  • EPS (TTM) -1.59
  • Earnings Date (est.) Apr 30, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 30.90

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

www.smmttx.com

265

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: SMMT

Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SMMT
7.86%
S&P 500 (^GSPC)
5.62%

1-Year Return

SMMT
34.68%
S&P 500 (^GSPC)
29.01%

3-Year Return

SMMT
981.54%
S&P 500 (^GSPC)
73.47%

5-Year Return

SMMT
152.98%
S&P 500 (^GSPC)
72.92%

Earnings Trends: SMMT

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -139.49M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-400M
-300M
-200M
-100M
0

Analyst Insights: SMMT

View More

Analyst Price Targets

12.05
30.90 Average
16.11 Current
45.16 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/4/2026
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 30 -> 23

Statistics: SMMT

View More

Valuation Measures

Annual
As of 5/1/2026
  • Market Cap

    12.51B

  • Enterprise Value

    11.93B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    22.91

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -1.21B

  • Diluted EPS (ttm)

    -1.59

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    713.45M

  • Total Debt/Equity (mrq)

    3.17%

  • Levered Free Cash Flow (ttm)

    --

Compare To: SMMT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: SMMT

Fair Value

16.11 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: